Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immutep Limited
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
May 28, 2026
Immutep Quarterly Activities Report Q3 FY26
May 22, 2026
Immutep Receives Nasdaq Notice of Bid Price Deficiency
May 22, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
April 29, 2026
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
March 19, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
February 12, 2026
←
Previous Page
1
2